Intestinal expression of the anti-inflammatory interleukin-1 homologue IL-37 in pediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 59, Issue 2, 2014, Pages

  Weidlich, Simon ^a   Bulau, Ana Maria ^a   Schwerd, Tobias ^a   Althans, Johanna ^a   Kappler, Roland ^a   Koletzko, Sibylle ^a   Mayr, Doris ^b   Bufler, Philip ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

cytokines; immunohistochemistry; inflammatory bowel disease; interleukin 37; pediatric

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CYTOKINE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 37; INTERLEUKIN 8; MESSENGER RNA; UNCLASSIFIED DRUG; AUTACOID; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOID CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS; WESTERN BLOTTING; COLON; GENETICS; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; UPREGULATION;

ADOLESCENT; CHILD; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKIN-17; INTERLEUKIN-18; INTESTINAL MUCOSA; MALE; RNA, MESSENGER; UP-REGULATION;

EID: 84904652665     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000387     Document Type: Article

References (36)

1. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008;14:4280-8.
2. Van Assche G, Vermeire S, Rutgeerts P. Infliximab therapy for patients with inflammatory bowel disease: 10 years on. Eur J Pharmacol 2009; 623 (suppl 1):S17-25.
3. Glocker EO, Kotlarz D, Boztug MD, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-45.
4. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52.
5. Pan G, Risser P, Mao W, et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001;13:1-7.
6. Busfield SJ, Comrack CA, Yu G, et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome. Genomics 2000;66:213-6.
7. Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010;11:1014-22.
8. Kumar S, Haning CR, Brigham-Burke MR, et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002;18:61-71.
9. Tilg H, Moschen AR. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J Hepatol 2011;55:960-2.
10. Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J Biol Chem 2000;275:1169-75.
11. Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 2002;99:13723-8.
12. Imaeda H, Takahashi K, Fujimoto T, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol 2013;172:410-6.
13. Sharma S, Kulk N, Nold ME, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol 2008;180:5477-82.
14. Grimsby S, Jaensson H, Dubrovska A, et al. Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its transcriptional activity. FEBS Lett 2004; 577:93-100.
15. Nold MF, Nold-Petry CA, Zepp JA, et al. Interleukin 37 exerts its antiinflammatory functions by associating with IL-18Ra and SIGIRR. Paper presented at: 9th Joint Meeting of ICS-ISICR; October 9-12, 2011; Florence, Italy.
16. McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A 2011;108:16711-6.
17. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007;133:423-32.
18. Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012;18:55-62.
19. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21.
20. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9.
21. Bufler P, Gamboni-Robertson F, Azam T, et al. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 2004;381 ((Pt 2)):503-10.
22. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
24. Bulau AM, Fink M, Maucksch C, et al. In vivo expression of interleukin- 37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal 2011;11:2480-90.
25. Turner D, Mack DR, Hyams J, et al. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis 2011;5:423-9.
26. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007;119:1113-9.
27. Kelsen J, Baldassano RN. Inflammatory bowel disease: the difference between children and adults. Inflamm Bowel Dis 2008;14 (suppl 2):S9-11.
28. Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011;22:127-47.
29. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999;162:6829-35.
30. Brand S. Crohn's disease: Th1 Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009;58:1152-67.
31. Horai R, Asano M, Sudo K, et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998;187:1463-75.
32. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36:388-400.
33. Glas J, Konard A, Schmechel S, et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. Am J Gastroenterol 2008;103:682-91.
34. Paul G, Khare V, Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 2012;42:95-109.
35. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009;41:71-6.
36. Zaki MH, Boyd KL, Kastan MB, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010;32:379-91.